Eli Lilly and Company (NYSE: LLY) revealed today that FDA has awarded emergency use authorization to its arthritis drug Baricitinib in combination with Gilead Sciences’ remdesivir for the treatment of COVID-19 patients in the hospital. FDA has allowed the emergency use for the